Finally, novel inhibitors of other DDR gene alterations are currently undergoing early phase trials to assess their safety and efficacy in melanomas with HRD (i.e., inhibitors of ATR, ATM, CHK1/2, and WEE1, among others) [183]. The gene discussed is ATM; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.